Technical Data
O7030-34B
Opioid Receptor, kappa, Internal (OPRK1, Opioid Receptor, kappa 1, Kappa-type Opioid Receptor, KOR, KOR-1, OPRK)
Description:
Opioid receptors are G-protein coupled receptors. Although the function of k-opioid receptors is unclear, recent evidence indicates that activation of the k-opioid receptor opposes a variety of mu-opioid receptor mediated actions throughout the brain and spinal cord. In general, opioids modulate numerous central and peripheral processes, including pain perception, neuroendocrine secretion and the immune response. The opioid signal is transduced from receptors through G proteins to various different effectors. Subsequent to G protein activation, several effectors are known to orchestrate the opioid signal. For example, activation of opioid receptors increases phosphatidylinositol turnover, activates K+ channels and reduces adenylyl cyclase and Ca++ channel activities.

Applications:
Suitable for use in Western Blot. Other applications not tested.

Recommended Dilution:
Western Blot: 1:1000
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. For long-term storage, aliquot and store at -20C. Aliquots are stable for at least 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
TypeIsotypeCloneGrade
PabIgGAffinity Purified
SizeStorageShippingSourceHost
10Blots4C (-20C Glycerol)Blue IceMouseRabbit
Concentration:
Not determined.
Immunogen:
Synthetic peptide derived from the internal region of the mouse k-opioid receptor.
Purity:
Purified by peptide affinity chromatography.
Form
Supplied as a liquid in PBS (without Mg2+ and Ca2+), pH 7.3, 1mg/ml BSA (IgG, protease free), 0.05% sodium azide, 50% glycerol.
Specificity:
Recognizes mouse opioid receptor. Species Crossreactivity: rat. Species sequence homology: human 93%.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Cichewicz, D.L., et al (2001) Changes in opioid and cannabinoid receptor protein following shortterm combination treatment with Delta9-tetrahydrocannabinoid and morphine. J. Pharmacol. Exp. Ther. 297(1):121-127. 2. Pan, Z.Z. (1998) mu-Opposing actions of the kappa-opioid receptor. Trends Pharmacol. Sci.19(3):94-98. 3. Piros, E.T., et al. (1996) Functional analysis of cloned opioid receptors in transfected cell lines. Neurochem. Res. (21)11:1277-1285.